Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2

Molecular Biology Reports

Volumn 38, Issue 4, 2011, Pages 2323-2328

  Tu, Chun Hua ^a   Liu, Wei Peng ^b   Dong, Mei ^c   Cai, Li Ping ^a   Mo, Ya Qin ^c   Yang, Dong Zi ^c  

^a NANCHANG UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemoprotection; Gene therapy; Ovarian specific promoter; Survivin

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; OVARIAN SPECIFIC PROMOTER 2; SURVIVIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BIRC5 PROTEIN, HUMAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVARY CELL CULTURE; PLASMID; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; ANALYSIS OF VARIANCE; ANIMAL; CRICETULUS; DRUG EFFECT; DRUG THERAPY; FLOW CYTOMETRY; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HAMSTER; METHODOLOGY; NEOPLASM; PROMOTER REGION;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG THERAPY; FLOW CYTOMETRY; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PROMOTER REGIONS, GENETIC; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION;

EID: 79960946726     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0365-y     Document Type: Article

References (28)

1. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Bertino JR (2002) Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587(2-3):164-173
2. Licht T, Goldenberg SK, Vieira WD, Gottesman MM, Pastan I (2000) Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice. Gene Ther 7(4):348-358
3. Kobayashi H, Takemura Y, Miyachi H (2001) Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum Cell 14(3):172-184
4. Chinnasamy N, Rafferty JA, Hickson I, Lashford LS, Longhurst SJ, Thatcher N, Margison GP, Dexter TM, Fairbaim LJ (1998) Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. Gene Ther 5(6):842-847
5. Bagchi S, Raychaudhuri P (2010) Damaged-DNA binding protein-2 drives apoptosis following DNA damage. Cell Div 5:3. doi: 10.1186/1747-1028-5-3
6. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14(16):5000-5005
7. Fukazawa T, Maeda Y, Durbin ML, Nakai T, Matsuoka J, Tanaka H, Naomoto Y, Tanaka N (2007) Pulmonary adenocarcinomatargeted gene therapy by a cancer-and tissue-specific promoter system. Mol Cancer Ther 6(1):244-252
8. Dorer DE, Nettelbeck DM (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61(7-8):554-571
9. Tu CH, Liu WP, Huang LL, Mo YQ, Yang DZ (2009) Cloning and transcriptional activity of a novel ovarian-specific promoter from rat retrovirus-like elements. Arch Biochem Biophys 485(1): 24-29
10. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 55-56
11. Sasaki Y, Saijo N, Lee YC, Takahashi H, Ishihara J, Sakurai M, Sano T, Nakano H, Kanzawa F, Hoshi A, Hamburger AW (1986) A bioassay of cisplatin by human tumor clonogenic assay. Jpn J Cancer Res 77(5):494-501
12. Siders WM, Halloran PJ, Fenton RG (1998) Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase. Cancer Gene Ther 5(5):281-291
13. Patterson A, Harris AL (1999) Molecular chemotherapy for breast cancer. Drugs Aging 14(2):75-90
14. Vandier D, Rixe O, Brenner M, Gouyette A, Besnard F (1998) Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res 58(20):4577-4580
15. Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW (2000) Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol 4(2):73-82
16. Saukkonen K, Hemminiki A (2004) Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 4(5):683-696
17. Wang W, Jin B, Li W, Xu CX, Cui FA, Liu B, Yan YF, Liu XX, Wang XL (2010) Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus. Mol Biol Rep 37(7):3239-3247
18. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20(9):2388-2399
19. James RI, Warlick CA, Diers MD, Gunther R, Mclvor RS (2000) Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity. Blood 96(4): 1334-1341
20. Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26(1):61-66
21. Zhou Y, Ling XL (2010) Establishment of a cisplatin-induced multidrug resistance cell line SK-Hep 1/DDP. Chin J Cancer 29(2):167-171
22. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, Van Buren G II, Samuel S, Kim MP, Lim SJ, Ellis LM (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69(5):1951-1957
23. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salevsen GS, Reed JC, Altieri DC (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279(93):34087-34090
24. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic largecell lymphoma. J Clin Oncol 22(9):1682-1688
25. Reed JC (2001) The survivin saga goes in vivo. J Clin Investig 108(7):965-969
26. Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5(2):65-72
27. Hennessy M, Spiers JP (2007) A primer on the mechanics of Pglycoprotein the multidrug transporter. Pharmacol Res 55(1): 1-15
28. Adams JM, Corry S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26(1):61-66